Regado Biosciences is at the forefront of developing innovative therapeutic technologies, focusing on creating two-component drug systems. These systems consist of a nuclease-stabilized RNA aptamer and a complementary oligonucleotide active control agent, allowing for precise control over therapeutic effects. The company's primary application is in the field of injectable antithrombotics, including anticoagulants and antiplatelet agents, targeting the acute and sub-acute care market. This market is substantial, valued in the billions, and demands safer and more controllable therapeutic options. Regado's technology aims to provide physicians with the ability to actively manage and personalize treatment, enhancing patient safety and outcomes. The business model revolves around the development and commercialization of these advanced therapeutic systems, generating revenue through partnerships, licensing agreements, and direct sales to healthcare providers.

Keywords: RNA aptamer, oligonucleotide, antithrombotics, anticoagulants, antiplatelet agents, acute care, sub-acute care, personalized medicine, therapeutic control, biotechnology.